seer-20220316

0001628280-22-006720.txt : 20220318 0001628280-22-006720.hdr.sgml : 20220318 20220318160543 ACCESSION NUMBER: 0001628280-22-006720 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220316 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20220318 DATE AS OF CHANGE: 20220318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Seer, Inc. CENTRAL INDEX KEY: 0001726445 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 821153150 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39747 FILM NUMBER: 22752526 BUSINESS ADDRESS: STREET 1: 3800 BRIDGE PARKWAY, SUITE 102 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-453-0000 MAIL ADDRESS: STREET 1: 3800 BRIDGE PARKWAY, SUITE 102 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Seer Biosciences, Inc. DATE OF NAME CHANGE: 20171226 8-K 1 seer-20220316.htm 8-K seer-20220316

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

March 16, 2022

Seer, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39747

82-1153150

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation)

File Number)

Identification No.)

3800 Bridge Parkway, Suite 102

Redwood City, California 94065

(Address of principal executive offices, including zip code)

650-453-0000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last reports)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Title of each class	Trading Symbol	Name of each exchange on which registered
Class A Common Stock, par value $0.00001 per share	SEER	The NASDAQ Stock Market LLC (The NASDAQ Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 16, 2022, Seer, Inc., (the “Company”) announced that Scott Thomas has been appointed to the role of Chief Commercial Officer, effective upon commencement of his employment with the Company on March 21, 2022 (the “Effective Date”).

Mr. Thomas previously served as Senior Vice President, Sales and Marketing at Singular Genomics Systems, a life sciences company focused on delivering genomic technologies, from May 2021 to March 2022. From August 2009 to May 2021, Mr. Thomas served in numerous roles with escalating commercial responsibilities at Illumina, a life science tools company. Most recently, Mr. Thomas served as Vice President, Global Commercial Strategy and Enablement at Illumina. Previously, he served as Vice President and General Manager of Illumina Japan, and Senior Director, Sales for Europe, Middle East and Africa. Mr. Thomas holds a B.A. in Public Relations from the University of Idaho, Moscow, a Master of Healthcare Administration from the University of Washington, Seattle and completed the Advanced Management Program at IESE Business School in Barcelona, Spain.

Under the terms of his offer letter, Mr. Thomas will receive an annual base salary of $395,000. Mr. Thomas will have a target annual cash bonus opportunity for calendar year 2022 equal to forty percent (40%) of his base salary, prorated to reflect the number of days in the year during which Mr. Thomas is employed with the Company. Mr. Thomas will also receive a sign-on bonus of $50,000, grossed up for taxes, provided that he agrees to re-pay the Company if he terminates employment before the two-year anniversary of the Effective Date.

The terms of Mr. Thomas’ offer letter also provide for the recommendation of a grant of a stock option to purchase 110,000 shares of the Company’s Class A common stock under the Company’s 2020 Equity Incentive Plan (the “Plan”) with an exercise price per share equal to the fair market value per share on the date of grant, which will be scheduled to vest as to 1/4th of the shares subject to the option on the one-year anniversary of the Effective Date and as to 1/48th of the shares each month thereafter, subject to his continued service to the Company through each applicable vesting date. Mr. Thomas’ offer letter also provides for the recommendation of a grant of an award of restricted stock units under the Plan of 26,000 shares of the Company’s Class A common stock that will be scheduled to vest as to 1/4th of the shares on the first Quarterly Vesting Date (as defined in the offer letter) on or immediately following the one-year anniversary of the Effective Date and as to 1/4th of the shares each year thereafter, subject to his continued service to the Company through each applicable vesting date.

Mr. Thomas will also be eligible to enter into a participation agreement under the Company’s Key Executive Change in Control and Severance Plan (the “Participation Agreement”), which will provide that if Mr. Thomas’ employment is terminated outside the period beginning on the date of a change in control and ending on the one-year anniversary date of such change in control (the “Change in Control Period”) either (1) by the Company without “cause” and not by reason of death or disability or (2) by the named executive officer as a “good reason termination” (as such terms are defined in the Participation Agreement), Mr. Thomas would be entitled to: (i) continued payments of base salary for a period of nine months following the date of such termination; and (ii) Company-paid COBRA continuation coverage for up to nine months. If, during the Change in Control Period, Mr. Thomas’ employment is terminated either (1) by the Company without cause and not by reason of death or disability or (2) by the named executive officer as a good reason termination, Mr. Thomas would be entitled to: (i) continued payments of base salary for a period of twelve months following the date of such termination; (ii) a cash payment equal to 100% of his annualized target bonus as in effect for the performance period in which such termination occurs, or if, greater, as in effect for the performance period in which the change in control occurs; (iii) Company-paid COBRA continuation coverage for up to twelve months; and (iv) vesting acceleration of 100% of the unvested portion of his then-outstanding time-based equity awards.

The severance benefits under the Participation Agreement will be subject to Mr. Thomas entering into and not revoking a separation agreement and release of claims with the Company as well as his compliance with the terms of any confidentiality, information and inventions agreements or other written agreement with the Company under which he has a material duty or obligation to the Company.

There is no arrangement or understanding between Mr. Thomas and any other persons pursuant to which Mr. Thomas was selected as Chief Commercial Officer. There are no family relationships between Mr. Thomas and any director or executive officer of the Company, and no transactions involving Mr. Thomas that would require disclosure under Item 404(a) of Regulation S-K.

The press release announcing Mr. Thomas’ appointment is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

ITEM 9.01

Financial Statements and Exhibits

Exhibit No.

Description

10.1 Confirmatory Offer Letter between the Registrant and Scott Thomas, effective March 21, 2022.

99.1 Press Release, dated March 16, 2022.

104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SEER, INC.

Date: March 18, 2022

By:

/s/ David Horn

David Horn

Chief Financial Officer

EX-9.1 2 pressreleaseccothomas.htm EX-9.1 Document

Ex 99.1

Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

Seasoned life sciences executive adds extensive global sales expertise to drive commercial efforts

REDWOOD CITY, Calif., March 16, 2022 – Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina.

“I’m thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented executive team,” said Omid Farokhzad, Chief Executive Officer and Chair of Seer. “As we accelerate our commercial efforts following the broad release of our Proteograph Product Suite, we’re excited to have Scott lead the expansion and building of our global commercial organization, and to leverage his extensive knowledge of markets around the world to reach and empower a broad range of customers to achieve exceptional outcomes.”

Prior to joining Singular Genomics, where he led the go-to-market strategy for the company’s next generation benchtop sequencer, consumables, and service products, Mr. Thomas served numerous roles with escalating commercial responsibilities at Illumina, most recently as Vice President, Global Commercial Strategy and Enablement. Previously he served as Vice President and General Manager of Illumina Japan, and Senior Director, Sales for Europe, Middle East and Africa. Before his tenure at Illumina, Mr. Thomas held roles for Providence Health and Services, Roche, and Abbott Laboratories.

“We’re at a pivotal time in the proteomics field, where unconstrained access to deep unbiased content can unlock biology; open entirely new markets and expand existing markets in ways previously not possible,” said Mr. Thomas. “The Proteograph Product Suite is uniquely able to provide deep access to the proteome at scale and drive the next wave of breakthrough scientific discoveries. I couldn’t be joining the Seer team at a more exciting time in the company’s journey,”

About Seer

Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the Company’s current views with respect to certain current and future events and performance. Such forward-looking statements are based on the Company’s beliefs and assumptions and on information currently available to it at the time of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding acceleration of commercial efforts, a global commercial organization, and a broad range of customers and outcomes. These and other risks are described more fully in the

Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other filings that the Company may make with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements, and specifically disclaims, any obligation to update any forward-looking statements.

Media Contact

Karen Possemato

pr@seer.bio

Investor Contact
Carrie Mendivil
investor@seer.bio

EX-10.1 3 confirmatoryemploymentlett.htm EX-10.1 Document

Ex 10.1

March 2, 2022

Scott Thomas

Re: Offer of Employment

Dear Scott,

I am pleased to offer you a position with Seer, Inc. (the “Company”) in accordance with the terms of this employment letter agreement (the “Agreement”).

1.Title; Position; Location. You will serve as the Company’s Chief Commercial Officer (CCO). You will report to the Company’s Chief Executive Officer (the “CEO”) and will perform the duties and responsibilities customary for such position and such other related duties as are reasonably assigned by the CEO or such officer designated by the CEO. You will perform your duties from your home office in Portland, OR, subject to frequent and customary travel as reasonably required by the Company and necessary to perform your job duties.

2.Base Salary. Your initial annual base salary will be $395,000, which will be payable, less any applicable withholdings, in accordance with the Company’s normal payroll practices. Your annual base salary will be subject to review and adjustment from time to time by our Board of Directors (our “Board”) or its Talent and Compensation Committee (the “Committee”), as applicable, in its sole discretion.

3.Annual Bonus. For the 2022 calendar year, your target annual cash bonus opportunity will be forty percent (40%) of your annual base salary, prorated to reflect the number of days in the year during which you are employed with the Company. Any annual bonus will be subject to performance and other criteria established by the Board or the Committee, as applicable, in its sole discretion, and subject to your continued employment through the date that the bonus is paid to you. Your annual bonus opportunity and the applicable terms and conditions may be adjusted from time to time by our Board or the Committee, as applicable, in its sole discretion, and no amount of any annual bonus is guaranteed.

4.Sign On Bonus. Upon employment, you will be eligible for a cash sign-on bonus of $50,000.00 (grossed up for taxes), provided that you agree to re-pay Seer the $50,000.00 if you terminate your employment with Seer before the two-year anniversary of your Start Date.

5.Equity Awards.

a.Stock Options. It will be recommended that, subject to the approval of the Board or the Committee, in its sole discretion, the Company grant you an award of stock options (the “Initial Option”) to purchase 110,000 shares of the Company’s Class A common stock (“Shares”) under the Company’s 2020 Equity Incentive Plan (or any successor plan, as applicable) and applicable option agreement thereunder, with an exercise price per Share equal to the fair market value per Share on the Initial Option’s date of grant, as determined by the Board or Committee, as applicable. For purposes of your Initial Option, “Vesting Commencement Date” means the date you commence employment with the Company. The Company will recommend that the Initial Option will be scheduled to vest as to one-fourth (1/4th) of the Shares subject to the Option on the one (1) year anniversary of the Optionee’s start date with the Company (or its Subsidiary, as applicable) as an Employee, and thereafter, as to one forty-eighth (1/48th) of the Shares subject to the Option on the same day of the month as the Optionee’s start date with the Company (or its Subsidiary, as applicable) as an Employee (or, if there is no corresponding day in a particular month, then on the last day of that month), in each case subject to the Optionee’s continued status as a Service Provider (as defined in the Plan) through the applicable vesting date.

b.Restricted Stock Units. It will be recommended that, subject to the approval of the Board or the Committee, in its sole discretion, the Company grant you an award of restricted stock units covering 26,000 Shares (the “Initial RSUs”). The Company will recommend that the Initial RSUs be scheduled to vest as to one-fourth (1/4th) of the Shares subject to the RSU Award on the first Quarterly Vesting Date (as defined below) on or immediately following the one (1) year anniversary of the RSU Award’s grant date, and thereafter, as to one-fourth (1/4th) of the Shares subject to the RSU Award each year for the next three (3) years on the same day of the year as the first vesting date, in each case subject to the Participant’s continued status as a Service Provider through the applicable vesting date. For purposes of the Initial RSUs, the Vesting Commencement Date means the Company’s first Quarterly Vesting Date that occurs on or after the date you commence employment with the Company. Quarterly Vesting Dates for the Company are the fifteenth (15th) day of each of February, May, August and November.

6.Employee Benefits. You will be eligible to participate in the benefit plans and programs established by the Company for its employees from time to time, subject to their applicable terms and conditions, including without limitation any eligibility requirements. The Company will reimburse you for reasonable travel or other expenses incurred by you in the furtherance of or in connection with the performance of your duties under this Agreement, pursuant to the terms of the Company’s expense reimbursement policy as may be in effect from time to time. The Company reserves the right to modify, amend, suspend or terminate the benefit plans, programs, and arrangements it offers to its employees at any time.

7.Severance. You will be eligible to participate in the Company’s Key Executive Change in Control and Severance Plan established for senior-level employees that is applicable to you consistent with your position within the Company. Additional information regarding such arrangement will be provided to you following your commencement of employment with the Company.

8.Confidentiality Agreement. As an employee of the Company, you will have access to certain confidential information of the Company and, during the course of your employment, you may develop certain information or inventions that will be the property of the Company. To protect the interests of the Company, you agree to sign and comply with an At-Will Employment, Confidential Information, Invention Assignment Agreement (the “Confidentiality Agreement”) which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non-disclosure of Company proprietary information. Please note that we must receive your signed Confidentiality Agreement before your first day of employment.

9.At-Will Employment. This Agreement does not imply any right to your continued employment for any period with the Company or any parent, subsidiary, or other affiliate of the Company. Your employment with the Company is for no specified period and constitutes at-will employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is free to conclude its employment relationship with you at any time, with or without cause, and with or without notice. We request that, in the event of resignation, you give the Company at least two weeks’ notice.

10.Protected Activity Not Prohibited. The Company and you acknowledge and agree that nothing in this Agreement limits or prohibits you from filing and/or pursuing a charge or complaint with, or otherwise communicating or cooperating with or participating in any investigation or proceeding that may be conducted by, any federal, state or local government agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board (“Government Agencies”), including disclosing documents or other information as permitted by law, without giving notice to, or receiving authorization from, the Company. In addition, nothing in this Agreement is intended to limit employees’ rights to discuss the terms, wages, and working conditions of their employment, nor to deny employees the right to disclose information pertaining to sexual harassment or any unlawful or potentially unlawful conduct, as protected by applicable law. You further understand that you are not permitted to disclose the Company’s attorney-client privileged communications or attorney work product. In addition, you acknowledge that the Company has provided you with notice in compliance with the Defend Trade Secrets Act of 2016 regarding immunity from liability for limited disclosures of trade secrets. The full text of the notice is attached in Appendix A.

11.Additional Employment Provisions. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your date of hire, or our employment relationship with you may be terminated. We also ask that, if you have not already done so, you disclose to the Company any and all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company’s understanding that any such agreements will not prevent you from performing the duties of your position and you represent that such is the case. During the term of your employment with the Company, you agree to perform your duties faithfully and to the best of your abilities and will devote your full business efforts and time to rendering services to the Company hereunder. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment, occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company. Nothing in this Agreement shall prohibit you from (a) making and managing passive investments, or (b) participating in professional and charitable organizations in an unpaid capacity, in a manner, and to an extent, that will not interfere with your duties or obligations to the Company, including under the Confidentiality Agreement. You agree not to bring any third party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will not in any way utilize any such information. As a Company employee, you will be expected to abide by the Company’s rules and standards. You agree that in the rendering of all services to the Company and in all aspects of employment with the Company, you will comply in all material respects with all lawful directives, policies, standards and regulations from time to time established by the Company. You will be required to sign an acknowledgment that you have read and that you understand the Company’s rules of conduct which are included in the Company Handbook.

12.Taxes. The Company (or its affiliate, as applicable) will have the right and authority to deduct from any payments or benefits under this Agreement all applicable federal, state, and local taxes or other required withholdings and payroll deductions (“Withholdings”). Prior to the payment of any amounts or provision of any benefits under this Agreement, the Company (and its affiliate, as applicable) is permitted to deduct or withhold, or require you to remit to the Company, an amount sufficient to satisfy any applicable Withholdings with respect to such payments and benefits. Neither the Company nor any of its affiliates will have any responsibility, liability or obligation to pay your taxes arising from or relating to any payments or benefits under this Agreement. This Agreement and the terms herein are intended to comply with or be exempt from the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations and any formal guidance promulgated thereunder (“Section 409A”), so that none of the payments and benefits to be provided hereunder will be subject to the additional tax imposed by Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to so comply or be so exempt. In no event will the Company or any of its affiliates have any responsibility, liability or obligation to reimburse or indemnify you, or hold you harmless, for any tax imposed, or other costs incurred, as a result of Section 409A.

To accept the Company’s offer, please sign and date in the spaces indicated below and return this Agreement to me. A duplicate original is enclosed for your records. If you accept our offer, your first day of employment will be March 21, 2022 (your “Start Date”). This Agreement, along with the Confidentiality Agreement, set forth the terms of your employment with the Company and supersede any prior representations or agreements including, but not limited to, any representations made during your recruitment, interviews or pre-employment negotiations, whether written or oral. This Agreement, including, but not limited to, its at-will employment provision, may not be modified or amended except by a written agreement signed by a duly authorized officer of the Company (excluding yourself). This Agreement will be

governed by the laws of the State of California but without regard to the conflict of law provision. This offer of employment will terminate if it is not accepted, signed and returned by March 4, 2022.

We look forward to your favorable reply and to working with you at Seer, Inc.

Sincerely,

SEER, INC.

By: /s/ Omid Farokhzad

Omid Farokhzad

Chief Executive Officer

Agreed to and accepted:

/s/ Scott Thomas

Dated: March 2, 2022

Appendix A

Section 7 of the Defend Trade Secrets Act of 2016

“ . . . An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that—(A) is made—(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. . . . An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual—(A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.”

EX-101.SCH 4 seer-20220316.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 seer-20220316_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Fiscal Period Focus Document Fiscal Period Focus Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Document Fiscal Year Focus Document Fiscal Year Focus EX-101.PRE 6 seer-20220316_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover Page	Mar. 16, 2022
Cover [Abstract]
Document Type	8-K
Document Period End Date	Mar. 16, 2022
Entity Registrant Name	Seer, Inc.
Entity File Number	001-39747
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-1153150
Entity Address, Address Line One	3800 Bridge Parkway
Entity Address, Address Line Two	Suite 102
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94065
City Area Code	650
Local Phone Number	453-0000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Class A Common Stock, par value $0.00001 per share
Trading Symbol	SEER
Entity Emerging Growth Company	false
Entity Central Index Key	0001726445
Document Fiscal Year Focus
Document Fiscal Period Focus
Amendment Flag	false

XML 8 seer-20220316_htm.xml IDEA: XBRL DOCUMENT 0001726445 2022-03-16 2022-03-16 false 0001726445 8-K 2022-03-16 Seer, Inc. DE 001-39747 82-1153150 3800 Bridge Parkway Suite 102 Redwood City CA 94065 650 453-0000 false false false false Class A Common Stock, par value $0.00001 per share SEER false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://seer.bio/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports seer-20220316.htm confirmatoryemploymentlett.htm pressreleaseccothomas.htm seer-20220316.xsd seer-20220316_lab.xml seer-20220316_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "seer-20220316.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "seer-20220316.htm" ] }, "labelLink": { "local": [ "seer-20220316_lab.xml" ] }, "presentationLink": { "local": [ "seer-20220316_pre.xml" ] }, "schema": { "local": [ "seer-20220316.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "seer", "nsuri": "http://seer.bio/20220316", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "seer-20220316.htm", "contextRef": "i108a8efdeac5475b80522af69f092978_D20220316-20220316", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://seer.bio/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "seer-20220316.htm", "contextRef": "i108a8efdeac5475b80522af69f092978_D20220316-20220316", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r4": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r5": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001628280-22-006720-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-006720-xbrl.zip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